Drugs, Cancer Drug | featured news

More than 100 cancer specialists have banded together to persuade pharmaceutical companies to bring prices down, suggesting that the high prices for medicine needed to keep someone alive is profiteering.

The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones. The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison.

The breast cancer drug Herceptin increases the risk of heart problems in elderly patients, especially those with a history of heart disease and/or ...

Cancer patients, brace yourselves. Many new drug treatments cost nearly $100,000 a year, sparking fresh debate about how much a few months more of life is worth.